Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT Forward 2
2025-522939-33-00Phase 2Authorised
- Sponsor
- argenx
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in myasthenia gravis (MG) comparing Empasiprubart IV monotherapy with Placebo IV (2 arms). Planned start Sep 2026; status: authorised.
02
Drugs
empasiprubart
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2025-522939-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522939-33-00.